IN2013MU01287A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01287A
IN2013MU01287A IN1287MU2013A IN2013MU01287A IN 2013MU01287 A IN2013MU01287 A IN 2013MU01287A IN 1287MU2013 A IN1287MU2013 A IN 1287MU2013A IN 2013MU01287 A IN2013MU01287 A IN 2013MU01287A
Authority
IN
India
Prior art keywords
pharmaceutical compositions
actives
pharmaceutical
dosage forms
diethylene glycol
Prior art date
Application number
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Madhavlal Govindlal Patel
Original Assignee
Themis Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51263451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU01287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201510577A priority Critical patent/UA119324C2/en
Priority to SG11201508006SA priority patent/SG11201508006SA/en
Priority to PE2015002110A priority patent/PE20151663A1/en
Priority to BR112015025172A priority patent/BR112015025172A2/en
Priority to PCT/IN2014/000207 priority patent/WO2014178065A1/en
Priority to CA2908571A priority patent/CA2908571C/en
Priority to AU2014261009A priority patent/AU2014261009B2/en
Priority to CN201480024878.7A priority patent/CN105392469A/en
Priority to JP2016505930A priority patent/JP6272454B2/en
Application filed by Themis Medicare Ltd filed Critical Themis Medicare Ltd
Priority to US14/242,973 priority patent/US9827315B2/en
Priority to IN1287MU2013 priority patent/IN2013MU01287A/en
Priority to MX2015013785A priority patent/MX2015013785A/en
Priority to KR1020177026610A priority patent/KR20170110728A/en
Priority to MA38544A priority patent/MA38544A1/en
Priority to KR1020157031380A priority patent/KR101875263B1/en
Publication of IN2013MU01287A publication Critical patent/IN2013MU01287A/en
Priority to PH12015502290A priority patent/PH12015502290B1/en
Priority to SA515361262A priority patent/SA515361262B1/en
Priority to HK16110701.1A priority patent/HK1222549A1/en
Priority to US15/292,810 priority patent/US20170027958A1/en
Priority to US15/801,390 priority patent/US10940205B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
IN1287MU2013 2013-04-02 2014-04-02 IN2013MU01287A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
UAA201510577A UA119324C2 (en) 2013-04-02 2014-02-04 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
KR1020157031380A KR101875263B1 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
MX2015013785A MX2015013785A (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives.
BR112015025172A BR112015025172A2 (en) 2013-04-02 2014-04-02 pharmaceutical composition
PCT/IN2014/000207 WO2014178065A1 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
CA2908571A CA2908571C (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
AU2014261009A AU2014261009B2 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing Diethylene glycol monoethyl ether or other alkyl derivatives
CN201480024878.7A CN105392469A (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
JP2016505930A JP6272454B2 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutically active ingredients comprising diethylene glycol monoethyl ether or other alkyl derivatives
SG11201508006SA SG11201508006SA (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
US14/242,973 US9827315B2 (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
IN1287MU2013 IN2013MU01287A (en) 2013-04-02 2014-04-02
PE2015002110A PE20151663A1 (en) 2013-04-02 2014-04-02 COMPOSITIONS OF PHARMACEUTICAL ACTIVE SUBSTANCES CONTAINING MONOETHYL ETHER DIETHYLENE GLYCOL OR OTHER ALKYL DERIVATIVES
KR1020177026610A KR20170110728A (en) 2013-04-02 2014-04-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
MA38544A MA38544A1 (en) 2013-04-02 2014-04-02 Compositions of active pharmaceutical ingredients containing monoethyl ether and diethylene glycol or other alkyl derivatives
PH12015502290A PH12015502290B1 (en) 2013-04-02 2015-10-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
SA515361262A SA515361262B1 (en) 2013-04-02 2015-10-04 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
HK16110701.1A HK1222549A1 (en) 2013-04-02 2016-09-08 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
US15/292,810 US20170027958A1 (en) 2013-04-02 2016-10-13 Fulvestrant compositions
US15/801,390 US10940205B2 (en) 2013-04-02 2017-11-02 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1287MU2013 IN2013MU01287A (en) 2013-04-02 2014-04-02

Publications (1)

Publication Number Publication Date
IN2013MU01287A true IN2013MU01287A (en) 2015-05-29

Family

ID=51263451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1287MU2013 IN2013MU01287A (en) 2013-04-02 2014-04-02

Country Status (17)

Country Link
US (2) US9827315B2 (en)
JP (1) JP6272454B2 (en)
KR (2) KR20170110728A (en)
CN (1) CN105392469A (en)
AU (1) AU2014261009B2 (en)
BR (1) BR112015025172A2 (en)
CA (1) CA2908571C (en)
HK (1) HK1222549A1 (en)
IN (1) IN2013MU01287A (en)
MA (1) MA38544A1 (en)
MX (1) MX2015013785A (en)
PE (1) PE20151663A1 (en)
PH (1) PH12015502290B1 (en)
SA (1) SA515361262B1 (en)
SG (1) SG11201508006SA (en)
UA (1) UA119324C2 (en)
WO (1) WO2014178065A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (en) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド Mucus-permeable coated particles, compositions, pharmaceutical compositions, pharmaceutical formulations, and methods for forming them
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
CN104546775B (en) * 2015-02-03 2017-08-25 山东新时代药业有限公司 A kind of atorvastatin agent
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017002030A1 (en) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Stable liquid formulations of melphalan
BR112018007486A2 (en) * 2015-10-13 2018-10-23 Nevakar Llc ready to inject fulvestrant composition and method for manufacturing an article containing a ready to inject fulvestrant composition
KR101634382B1 (en) * 2015-10-20 2016-06-28 미래제약 주식회사 Oral liquid formulation of tadalafil
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US20180325813A1 (en) * 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
WO2017132243A1 (en) * 2016-01-29 2017-08-03 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
CN109069651A (en) 2016-04-13 2018-12-21 诺迪克控股公司 Stable Nimodipine parenteral administration
KR20190109604A (en) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018005676A1 (en) * 2016-06-28 2018-01-04 Chimerix, Inc. Formulations of brincidofovir
US20190282500A1 (en) 2016-09-09 2019-09-19 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
FR3057775B1 (en) * 2016-10-26 2018-11-02 Crossject PHARMACEUTICAL SOLUTION OF HYDROCORTISONE FOR INJECTION DEVICE
BE1024559B1 (en) * 2017-02-21 2018-04-05 Purna Pharmaceuticals Nv Process for making a sprayable emulsion comprising a corticosteroid, an aminoglycoside and an acid
CN108721209A (en) * 2017-04-20 2018-11-02 广东东阳光药业有限公司 A kind of azithromycin injection for animals
JP7299166B2 (en) * 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド Precipitation-resistant small molecule drug formulation
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20190142789A1 (en) * 2017-08-09 2019-05-16 Piedmont Animal Health, Llc Therapeutic formulations and uses thereof
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
MX2020005517A (en) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Crystal forms and production methods thereof.
BR112020011189A2 (en) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. non-racemic mixtures and uses thereof
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN110314158A (en) * 2018-03-22 2019-10-11 深圳澳美制药技术开发有限公司 Tioconazole composition and preparation method thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
CN109364021A (en) * 2018-10-26 2019-02-22 山西普德药业有限公司 A kind of injection vinpocetine
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2021015247A (en) 2019-06-14 2022-02-11 Propella Therapeutics Inc Topical acyclovir formulations and uses thereof.
CN116474218A (en) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 Pharmaceutical fluid dispenser and dexmedetomidine nasal spray for maintaining uniformity of administration
US11135208B2 (en) 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use
CN114728014A (en) * 2019-11-01 2022-07-08 皮埃蒙特动物健康公司 Therapeutic formulations and uses thereof
US20230073803A1 (en) * 2019-12-16 2023-03-09 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase - 2 inhibitors
CN111632029B (en) * 2020-06-28 2021-05-07 江苏吴中医药集团有限公司 Methocarbamol injection and preparation method thereof
CN112315905B (en) * 2020-12-07 2021-11-30 安徽海洋药业有限公司 Artemether injection and preparation method thereof
CN112370422B (en) * 2020-12-09 2023-03-03 南京联智医药科技有限公司 Drotaverine hydrochloride injection stabilized by substituted beta-cyclodextrin and preparation method thereof
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113004301B (en) * 2021-03-11 2022-02-18 广西师范大学 Artesunate-based-diphenylurea derivative ARS-DPU as well as preparation method and application thereof
CN113069527B (en) * 2021-04-20 2022-03-18 北京华睿鼎信科技有限公司 Composition with functions of dispelling effects of alcohol and protecting liver and preparation method thereof
CN115702936A (en) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 Lucotinib composition and application thereof
FR3128874A1 (en) * 2021-11-09 2023-05-12 Crossject Pharmaceutical solution of hydrocortisone for injection device
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
FR2756736B1 (en) * 1996-12-05 1999-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
KR100382347B1 (en) * 2000-10-30 2003-05-01 에스케이케미칼주식회사 Sheet-shaped heating element and method of preparing the same
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US6551615B1 (en) * 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1501925A4 (en) * 2002-05-17 2006-10-25 New Horizons Diagnostics Corp Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
JP4542743B2 (en) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 Solution pharmaceutical composition of pyridone derivatives
PL1830885T3 (en) * 2004-12-21 2009-04-30 Intervet Int Bv Injectable veterinary composition comprising florfenicol
WO2007070562A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Non-hygroscopic compositions of enterostatin
WO2009066146A2 (en) * 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
US8128913B1 (en) * 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
KR101096429B1 (en) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 Oral Soft Capsule of Aceclofenac Having Improved Stability
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2473161B1 (en) * 2009-08-31 2017-05-17 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9737478B2 (en) * 2009-09-28 2017-08-22 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) Treatment of malaria
US8470886B2 (en) * 2009-11-27 2013-06-25 Nuvo Research Inc. Topical ibuprofen formulations
EP2575813A1 (en) * 2010-05-28 2013-04-10 Nuvo Research Inc. Topical etoricoxib formulation
US8747818B1 (en) * 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
PT2704703T (en) * 2011-05-03 2019-10-25 Aponia Laboratories Inc Transdermal compositions of ibuprofen and methods of use thereof
CU24287B1 (en) * 2012-06-27 2017-12-08 Medincell SUPPLY OF BIODEGRADABLE DRUG FOR HYDROPHOBIC COMPOSITIONS

Also Published As

Publication number Publication date
KR20150126067A (en) 2015-11-10
PE20151663A1 (en) 2015-12-03
CA2908571C (en) 2018-11-06
CA2908571A1 (en) 2014-11-06
PH12015502290A1 (en) 2016-02-01
KR20170110728A (en) 2017-10-11
JP6272454B2 (en) 2018-01-31
AU2014261009A1 (en) 2015-10-29
US20180071390A1 (en) 2018-03-15
PH12015502290B1 (en) 2016-02-01
MX2015013785A (en) 2016-08-19
WO2014178065A1 (en) 2014-11-06
SA515361262B1 (en) 2018-08-18
BR112015025172A2 (en) 2017-07-18
US9827315B2 (en) 2017-11-28
SG11201508006SA (en) 2015-10-29
HK1222549A1 (en) 2017-07-07
AU2014261009B2 (en) 2017-05-04
US10940205B2 (en) 2021-03-09
JP2016515609A (en) 2016-05-30
CN105392469A (en) 2016-03-09
UA119324C2 (en) 2019-06-10
MA38544A1 (en) 2017-03-31
US20140296191A1 (en) 2014-10-02
KR101875263B1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
PH12015502290B1 (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
BR112018008880A8 (en) 7- (thiazol-5-yl) pyrrolopyrimidine compound as IR17 agonist
NZ709958A (en) Enhanced stability of novel liquid compositions
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX351584B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
BR112014009087A2 (en) xylitol stabilized etanercept formulations
BR112015000229A2 (en) stable aqueous formulations of etanercept
EA033811B1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
EA201500742A1 (en) PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
DOP2015000005A (en) DERIVATIVES OF ESTRA 1,3,5 (10), 16 TETRAENE 3 SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
AR090073A1 (en) N-ETIL-N-PHENYL-1,2-DIHIDRO-4,5-DI-HYDROXI-1-METHYL-2-OXO-3-CHINOLINACARBOXAMIDE, ITS PREPARATION AND USES
MX368635B (en) Tricyclic piperidine compounds.
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
PH12016501117A1 (en) Pharmaceutical compositions of carotenoid
MX359887B (en) Chewable composition for oral administration and process for preparing thereof.
BR112015015250A2 (en) pyrrolidine derivatives, pharmaceutical compositions and uses thereof
PE20160850A1 (en) MULTIPARTICULATE SYSTEM FOR ADMINISTERING DRUGS
ES2422563A1 (en) Injectable pharmaceutical composition of ibuprofen and arginine, its preparation procedure, unit dosage form and use thereof (Machine-translation by Google Translate, not legally binding)
BR112015014180A2 (en) gel compositions
UA107631C2 (en) PHARMACEUTICAL COMPOSITION OF MEDICINAL PRODUCT OF SEDATIVE AND SPASMOLITIC ACTION IN THE FORM OF SOFT GELATIN Capsules (OPTIONS)
UY35329A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME.
UA97076C2 (en) Anti-inflammatory ointment based on sulfanilamide
TH163846B (en) Composition of active pharmaceutical ingredients containing diethylene glycol, monoethyl ether or other alkyl derivatives.
TH159989B (en) Nicotine composition
FR2978350B1 (en) LEVOMILNACIPRAN-BASED MEDICINAL PRODUCT FOR FUNCTIONAL REHABILITATION AFTER ACUTE NEUROLOGICAL ACCIDENT